Results 141 to 150 of about 26,268,552 (306)

Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies for Helicobacter pylori Eradication in High Clarithromycin Resistance Areas

Antibiotics
Background and aim: We conducted an equivalence trial of quadruple non-bismuth “concomitant” and “hybrid” regimens for H. pylori eradication in a high clarithromycin resistance area. Methods: There were 321 treatment-naïve H.
Sotirios D. Georgopoulos, Elias Xirouchakis, Christos Liatsos, Pericles Apostolopoulos, Panagiotis Kasapidis, Beatriz Martinez-Gonzalez, Fotini Laoudi, Maria Stoupaki, Georgios Axiaris, Dionysios Sgouras, Andreas Mentis, Spyridon Michopoulos   +11 more
doaj   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Timdarpacept (IMM01) combined with azacitidine (AZA) as first-line therapy in adults with higher risk chronic myelomonocytic leukemia (CMML): results from a prospective, multicenter, phase II study

Experimental Hematology & Oncology
Background Timdarpacept (IMM01) is a recombinant signal regulatory protein α–IgG1 fusion protein that exerts antitumor activity by blocking the “don’t eat me” signal while simultaneously activating the “eat me” signal, inducing robust antibody-dependent ...
Liya Ma, Wei Yang, Sujun Gao, Junmin Li, Qingsong Yin, Xingli Zhao, Xiaojing Yan, Sanfang Tu, Fei Li, Haiping Yang, Ronghua Hu, Shaoyuan Wang, Zheng Dong, Xiwen Zhao, Guodong Lu, Zhuli Wu, Wenzhi Tian, Hongyan Tong, Zhijian Xiao   +18 more
doaj   +1 more source

[Behavioural activation as a first-line treatment for depression].

Nederlands tijdschrift voor geneeskunde, 2017
Contains fulltext : 173065.pdf (Publisher’s version ) (Open Access)
Eijndhoven, P.F. van, Schene, A.H.
openaire   +3 more sources

Soft motions encoded by the fold and mediated by conserved hinge sites drive V‐ATPase allosteric machinery and autoinhibition

FEBS Letters, EarlyView.
Vacuolar H+‐ATPase (V‐ATPase) is a multisubunit rotary proton pump that acidifies intracellular compartments. Using elastic network models, we identified conserved hinge residues that govern its large‐scale functional motions. We show that intrinsically encoded ‘soft modes’ drive critical functional transitions, including rotary catalysis and ...
Diksha Parwana, Xiaowei Bogetti, Stuti Sharma, Ivet Bahar   +3 more
wiley   +1 more source

Planned first-line bilateral femoral access for endovascular treatment of unilateral common iliac artery chronic total occlusion: procedural control and outcomes

Archives of Medical Science: Atherosclerotic Diseases
Introduction Chronic total occlusion (CTO) of the common iliac artery (CIA) represents a technically challenging subset of aorto-iliac occlusive disease, particularly when the lesion extends close to the aorto-iliac bifurcation.
Emced Khalil
doaj   +1 more source

How structural disorder and polyelectrolyte properties of prothymosin α enable its large interactome

FEBS Letters, EarlyView.
In this review, complexes of the fully disordered and highly negatively charged prothymosin α are collected, described, and discussed. Linked to its poly‐electrostatic character, prothymosin α engages a large interactome through multiple different binding modes ranging from fully disordered complexes to short linear motif (SLiM)‐driven interactions ...
Ketty C. Tamburrini, Freia S. Buus, Benjamin Schuler, Birthe B. Kragelund   +3 more
wiley   +1 more source

Role of lapatinib in the first-line treatment of patients with metastatic breast cancer

Cancer Management and Research, 2010
Catherine Oakman, Marta Pestrin, Elena Zafarana, Egidia Cantisani, Angelo Di Leo“Sandro Pitigliani” Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Piazza Ospedale 2, 59100, Prato, ItalyAbstract: Lapatinib is a dual
Catherine Oakman, Marta Pestrin, Elena Zafarana, et al   +3 more
doaj  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source